Big Drop in Cervical Cancer Deaths; Publication Hijackers; A Win for CRC Home Tests

Cervical cancer mortality in American women younger than 25 declined by 62% from 2016 to 2021, coinciding with uptake of the vaccine against human papillomavirus. (JAMA)

An oncologist fends off burnout with poetry. (Oncology News Central)

Adding capivasertib (Truqap) to abiraterone (Zytiga) and androgen deprivation therapy improved radiographic progression-free survival in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer, AstraZeneca announced.

Roche said that adding the TIGIT inhibitor tiragolumab to atezolizumab (Tecentriq) did not improve overall survival in untreated PD-L1-high metastatic non-small cell lung cancer.

Publication hijackers, once targeting mostly small and independent publishers, have expanded their sights to include major labels. (Retraction Watch)

More evidence that home testing kits improve screening rates for colorectal cancer. (UNC Lineberger Comprehensive Cancer Center, JAMA Network Open)

Women with cancer reported better mental health status after participating in a program of yoga and psychological skill development. (UF Health Cancer Center, Integrative Cancer Therapies)

An experimental chemotherapy-free treatment for ovarian cancer reduced tumor size and improved survival in laboratory studies. (Wistar Institute, Journal of Experimental Medicine)

Meanwhile, adjuvant therapy that included chemotherapy led to better survival in patients with rectal cancer that had been upstaged from T2 to T3. (Fox Chase Cancer Center/Temple Health, Journal of Gastrointestinal Surgery)

Guardant Health announced that a California jury awarded the company almost $300 million after unanimously deciding that Natera intentionally misled cancer specialists about the Guardant Reveal test for early colorectal cancer detection in favor of Natera’s Signatera test.

Please enable JavaScript to view the

comments powered by Disqus.